ライフサイエンスコーパス: antipsychotic

1 and the molecular effects of a prototypical antipsychotic.

2 ontrolled treatment with a second-generation antipsychotic.

3 ychosis show a better subsequent response to antipsychotics.

4 or antagonists, such as typical and atypical antipsychotics.

5 both first-generation and second-generation antipsychotics.

6 n Registry provided data on prescriptions of antipsychotics.

7 sorder, and 85.5% were receiving concomitant antipsychotics.

8 little difference between second-generation antipsychotics.

9 fects in schizophrenia patients treated with antipsychotics.

10 ced by dopamine receptor blockers, including antipsychotics.

11 zapine compared with other second-generation antipsychotics.

12 er there are significant differences between antipsychotics.

13 atients unlikely to respond to non-clozapine antipsychotics.

14 the motor-reducing and cataleptic effects of antipsychotics.

15 regardless of whether they were also taking antipsychotics.

16 visits for adverse drug events, followed by antipsychotics (4.5%; 95% CI, 3.3%-5.6%).

17 nificant enrichment both in known targets of antipsychotics (70 genes, p=0.0078) and novel predicted

18 The efficacy of antipsychotics across the initial severity range in pati

19 igrostriatal dopamine release (which conveys antipsychotic action), they are expressed almost exclusi

20 iperazine 16c, which unequivocally displayed antipsychotic activity in vivo.

21 ivity at the 5-HT2C receptor with respect to antipsychotic activity.

22 -line treatment with either first-generation antipsychotics (adjusted hazard ratio, 3.06; 95% CI, 1.3

23 .06; 95% CI, 1.32-7.05) or second-generation antipsychotics (adjusted hazard ratio, 3.44; 95% CI, 1.7

24 2.89; 95% CI, 1.51 to 5.55; P=0.001), or an antipsychotic agent (hazard ratio, 3.02; 95% CI, 1.34 to

25 st-generation and several recently-developed antipsychotic agents.

26 mplications for understanding the actions of antipsychotic agents.

27 fracture, 1.48; 95% CI, 1.18-1.85; P < .05), antipsychotics (aHR for MOF, 1.43; 95% CI, 1.15-1.77; P

28 Since these receptors are major targets of antipsychotic and anti-Parkinsonian drugs, a better char

29 Moderate and high-dose antipsychotic and antidepressant use were associated wit

30 more likely to receive a prescription for an antipsychotic and more likely to receive one conforming

31 olunteers, a condition that was unrelated to antipsychotic and/or anxiolytic medication.

32 ere enrolled: 353 who used second-generation antipsychotics and 134 comparison women.

33 for bipolar disorder were enriched for both antipsychotics and antidepressants.

34 of the evidence, recommend reserving use of antipsychotics and other sedating medications for treatm

35 UM-ACB), any antipsychotic prescription (PUM-antipsychotic), and any PUM exposure (any-PUM).

36 ensitivity of thalamocortical projections to antipsychotics, and an abnormal acoustic-startle respons

37 r use of mood stabilizers, by 60% for use of antipsychotics, and by 13% for use of benzodiazepines.

38 use of mood stabilizers, by 171% for use of antipsychotics, and by 31% for use of benzodiazepines.

39 d glutamate homoeostasis, impaired action of antipsychotics, and development of antipsychotic resista

40 S: Central neuromodulators (antidepressants, antipsychotics, and other central nervous system-targete

41 e (n=12) who had not responded to first-line antipsychotics, and patients who had responded to first-

42 ions included were antidepressants, atypical antipsychotics, anticonvulsants, lithium, and other medi

43 hylb enzene-1-sulfonamide) exhibited a broad antipsychotic-, antidepressant-, and anxiolytic-like act

44 mulative low, moderate, and high exposure to antipsychotics, antidepressants, and benzodiazepines fro

45 ntidementia drugs, alone and in combination, antipsychotics, antidepressants, anxiolytics, and hypnot

46 ed prescription of psychotropic medications (antipsychotics, antidepressants, psychostimulants, drugs

47 The frequency of antipsychotic (AP) use during pregnancy has approximatel

48 ly used to treat pathologies for which other antipsychotics are indicated because it displays fewer s

49 Second-generation antipsychotics are used to treat a spectrum of psychiatr

50 human disease gene, identified the atypical antipsychotic aripiprazole as one of the hits.

51 group, n = 506); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group,

52 Further analysis pointed to antipsychotics as having independent enrichment after re

53 imately twice as many patients improved with antipsychotics as with placebo, but only a minority expe

54 vidual variability in the predisposition for antipsychotic-associated weight gain.

55 viewed the available evidence and found that antipsychotics can be reduced or discontinued in a subst

56 Typical antipsychotics can cause disabling side effects.

57 and tolerability of cariprazine, an atypical antipsychotic candidate, in adult patients with acute bi

58 We aimed to assess the new generation antipsychotic cariprazine in adult patients with predomi

59 deacetylase (HDAC) inhibitors, but not other antipsychotics, chemical chaperones, or VPA structural a

60 Antipsychotic clinical response occurred at a threshold

61 The antipsychotic clozapine is uniquely effective in the man

62 early 1990s when studies showed the atypical antipsychotic clozapine possessed higher affinity for D4

63 s carvedilol and labetalol, and the atypical antipsychotic clozapine, in reversing MDMA-induced brain

64 se-dependent manner, similar to the atypical antipsychotic, clozapine.

65 The antipsychotic compound chlorpromazine is a widely used t

66 Antipsychotics differed substantially in side effects.

67 (hazard ratio=0.78, 95% CI=0.69-0.88), index antipsychotic discontinuation (hazard ratio=0.60, 95% CI

68 METHOD: In the Antipsychotic Discontinuation in Alzheimer's Disease tri

69 In the Antipsychotic Discontinuation in Alzheimer's Disease tri

70 tions, particularly auditory hallucinations, antipsychotic discontinuation should be approached cauti

71 Effects of age, antipsychotic dose, and symptom severity were determined

72 o association with age, symptom severity, or antipsychotic dose.

73 ptom severity despite substantial and stable antipsychotic doses.

74 tients' cognitive flexibility impairment and antipsychotic dosing were negatively correlated with pat

75 Defining the mechanisms of action of the antipsychotic drug (APD), clozapine, is of great importa

76 reductions, 32 strategies that augmented any antipsychotic drug and 5 strategies that augmented cloza

77 ompared separately for combinations with any antipsychotic drug and for combinations with clozapine.

78 of a formal structural hybridization of the antipsychotic drug aripiprazole and the heterocyclic cat

79 further highlight p110delta as a target for antipsychotic drug development.

80 Antipsychotic drug efficacy may have decreased over rece

81 Here we demonstrate that chronic antipsychotic drug exposure increases nuclear translocat

82 ry management of schizophrenia regardless of antipsychotic drug exposure.

83 antimetastatic potential of penfluridol, an antipsychotic drug frequently prescribed for schizophren

84 receptor in its inactive state bound to the antipsychotic drug nemonapride, with resolutions up to 1

85 There was a large reduction in antipsychotic drug prescription in dementia from 22.1% (

86 electrochemical ligand-binding approach for antipsychotic drug screening where competitive binding o

87 ferentially methylated genes and 49 genes as antipsychotic drug targets.

88 uthors recently demonstrated that successful antipsychotic drug treatment alters resting-state functi

89 Clinical response to antipsychotic drug treatment is highly variable, yet pro

90 phrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic

91 D2LR signaling mediated effects of a typical antipsychotic drug, haloperidol, in inducing catalepsy b

92 ty model, compound (+)-19 showed significant antipsychotic-drug-like activity.

93 phase schizophrenia and minimal exposure to antipsychotic drugs (<2 years), who underwent resting st

94 Atypical antipsychotic drugs (APDs) have been hypothesized to sho

95 Current antipsychotic drugs (APDs) show efficacy with positive s

96 All FDA-approved antipsychotic drugs (APDs) target primarily dopamine D2

97 igm shift due to development of new atypical antipsychotic drugs (APDs), with better tolerability due

98 the pharmacology of a new class of glutamate antipsychotic drugs and their crosstalk mechanism throug

99 However, antipsychotic drugs are not clinically effective at reve

100 te transporters moderate CNS availability of antipsychotic drugs are summarised.

101 Typical antipsychotic drugs are widely thought to alleviate the

102 ed clinical trials comparing the efficacy of antipsychotic drugs combined with other antipsychotic or

103 At present, treatment mainly consists of antipsychotic drugs combined with psychological therapie

104 y of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia.

105 thought to be the primary mode of action of antipsychotic drugs in alleviating psychotic symptoms.

106 ety and efficacy of antidepressants added to antipsychotic drugs in the treatment of schizophrenia.

107 The differential response to first-line antipsychotic drugs may reflect a different underlying n

108 Current antipsychotic drugs produce fairly robust clinical benef

109 Antipsychotic drugs remain the standard for schizophreni

110 relevant randomised controlled trials of 12 antipsychotic drugs that involved 2669 participants.

111 ty disorder drugs, antidepressant drugs, and antipsychotic drugs) comparing the 10- to 36-month perio

112 addressed by antidepressant, anxiolytic, and antipsychotic drugs, often administered off-label.

113 for a scientific commentary on this article.Antipsychotic drugs, originally developed to treat schiz

114 els play a role in the therapeutic action of antipsychotic drugs, particularly risperidone, and furth

115 results show increasing enrichment for known antipsychotic drugs, selective calcium channel blockers,

116 isorders, making those receptors targets for antipsychotic drugs.

117 rapeutic efficacy in comparison with current antipsychotic drugs.

118 ch is likely to affect the mode of action of antipsychotic drugs.

119 coupled receptor that is a common target for antipsychotic drugs.

120 prospective treatment with second-generation antipsychotic drugs.

121 s among infants exposed to second-generation antipsychotics during pregnancy relative to a comparison

122 ine receptor D2, are immediately relevant to antipsychotic effects or represent novel antipsychotic t

123 The limited antipsychotic efficacy and high level of adverse events

124 eimer's disease, the mechanisms underpinning antipsychotic efficacy and side effects are poorly under

125 zophrenia, but the mechanisms underlying the antipsychotic efficacy of muscarinic modulators are not

126 concurrent behavioral effects predictive of antipsychotic efficacy.

127 , lamotrigine, carbamazepine, oxcarbazepine, antipsychotics, electroconvulsive therapy and various li

128 The odds of PUM-antipsychotic exposure were also greater in dual users (

129 se, race/ethnicity, and minimal (</=2 weeks) antipsychotic exposure were performed.

130 djusted hazard ratio=0.75, 95% CI=0.63-0.89) antipsychotic exposures were associated with substantial

131 f adverse event profiles when choosing among antipsychotics for children and adolescents who often re

132 ials.gov for randomised controlled trials of antipsychotics for the acute treatment of first-episode

133 ans); and (iii) 18F-fallypride imaging of an antipsychotic free Alzheimer's disease control group (n

134 AR VT was HCs > antipsychotic treated SZCs > antipsychotic free SZCs.

135 efrontal cortex (mPFC) have been reported in antipsychotic-free patients with schizophrenia.

136 In the first such study in antipsychotic-free schizophrenia, we have used [(11)C](R

137 a "minimal" response occurred in 51% of the antipsychotic group versus 30% in the placebo group, and

138 The pooled antipsychotic group was associated with a higher inciden

139 k-taking behaviors, in a fashion akin to the antipsychotic haloperidol and the mood stabilizer lithiu

140 issue from mice chronically treated with the antipsychotic haloperidol or vehicle.

141 nd the prescription of potentially hazardous antipsychotics halved after the introduction of national

142 What is less clear is why antipsychotics have a therapeutic latency of weeks.

143 f randomized clinical trials (RCTs) of other antipsychotics have been published.

144 s metabolite paliperidone and other atypical antipsychotics have similar potencies for the two isofor

145 95% CI=0.55-0.65), and use of an additional antipsychotic (hazard ratio=0.76, 95% CI=0.70-0.82).

146 higher mortality during treatment with other antipsychotics (hazard ratio: 1.45, 95% CI: 0.86-2.45).

147 a (12.9% for clozapine vs. 8.5% for standard antipsychotic; hazard ratio=1.40, 95%CI=1.09-1.78), and

148 us (2.8% for clozapine vs. 1.4% for standard antipsychotic; hazard ratio=1.63, 95% CI=0.98-2.70), hyp

149 on (0.9% for clozapine vs. 0.3% for standard antipsychotic; hazard ratio=2.50, 95% CI=0.97-6.44).

150 schizophrenia show an inadequate response to antipsychotics-ie, treatment resistance.

151 y modest benefit to suboptimal responders to antipsychotics, if any.

152 ssants adjunctive to a mood stabiliser or an antipsychotic in patients with acute bipolar depression.

153 lled or usual care (UC) controlled trials of antipsychotics in adult patients with delirium.

154 pical (haloperidol) and atypical (clozapine) antipsychotics in MET mice mimicked effects in human sch

155 he index antipsychotic, use of an additional antipsychotic, incidence of serious medical conditions,

156 tformin treatment was effective in improving antipsychotic-induced dyslipidemia and insulin resistanc

157 nsulin resistance, and the effects improving antipsychotic-induced insulin resistance appeared earlie

158 revious interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic di

159 xamine the efficacy of metformin in treating antipsychotic-induced weight gain and other metabolic ab

160 Insufficient evidence exists on which antipsychotic is more efficacious for patients with trea

161 -specific betaarr2-KO mice, we show that the antipsychotic-like effects of a betaarr2-biased D2R liga

162 monstrate a novel mechanism for the putative antipsychotic-like properties of CBD in the mesolimbic c

163 onists have been shown to have procognitive, antipsychotic-like, anxiolytic, weight-reducing, glucose

164 associated with positive symptoms (p<0.007), antipsychotic load (p<0.015), hedonic effects of AMPH (p

165 ionship between risk of death and cumulative antipsychotic load, and even less about the relationship

166 We review evidence suggesting that antipsychotics may counter both the increased propensity

167 erlap between schizophrenia pathogenesis and antipsychotic mechanism of action.

168 d-amphetamine, on PPI and neurocognition in antipsychotic-medicated schizophrenia patients and healt

169 Amphetamine acutely 'normalized' PPI in antipsychotic-medicated schizophrenia patients; no concu

170 ed for time-variant (other illicit drug use, antipsychotic medication adherence) and time-invariant (

171 (mean [SD] age, 37.6 [12.0] years) initiated antipsychotic medication in a variety of prescriber spec

172 onfounded by potential modulatory effects of antipsychotic medication on microglial activity.

173 ression in rodents treated for 9 months with antipsychotic medication suggests that our findings are

174 e striatal blood flow during active atypical antipsychotic medication treatment and after at least 3

175 Antipsychotic medication used for behaviour should be re

176 Samples with a higher proportion of antipsychotic medication users showed larger caudate vol

177 he striatum (the primary locus of action for antipsychotic medication), and receives GABAergic and gl

178 s suggest that in the context of appropriate antipsychotic medication, a low dose of amphetamine enha

179 ychosis, less than 6 weeks of treatment with antipsychotic medication, and a score of 4 or more on at

180 patients investigated thus far have been on antipsychotic medication, and as these compounds may dam

181 re new initiation of clozapine or a standard antipsychotic medication, defined as no exposure to the

182 After at least 5 days' withdrawal from all antipsychotic medication, patients were randomly assigne

183 .2-6.3%), independent of body mass index and antipsychotic medication, suggesting shared genetic comp

184 ) or placebo (N=45) alongside their existing antipsychotic medication.

185 ; 95% CI, 0.44-0.77) compared with no use of antipsychotic medication.

186 eased risk of relapse and non-adherence with antipsychotic medication.

187 condary effects of illness chronicity and/or antipsychotic medication.

188 adults (age, 18-64 years) who were starting antipsychotic medication.

189 de of psychosis who have not been exposed to antipsychotic medication.

190 e with a prescription for an antidementia or antipsychotic medication.

191 I, 0.53-0.63) and all long-acting injectable antipsychotic medications (HRs 0.65-0.80) were associate

192 Atypical antipsychotic medications are indicated for the treatmen

193 In Alzheimer's disease, antipsychotic medications are often used for a period, w

194 n whereby CBD can produce effects similar to antipsychotic medications by triggering molecular signal

195 nations and delusions, prolonged exposure to antipsychotic medications leads to cognitive deficits in

196 e striatum, where D2 receptors are abundant, antipsychotic medications may affect neural function in

197 n found that SERMs, antifungals, and several antipsychotic medications reduced levels of 7-DHC.

198 atment for schizophrenia involves the use of antipsychotic medications that block DA receptor transmi

199 Long-acting injectable antipsychotic medications were associated with substanti

200 Clozapine and long-acting injectable antipsychotic medications were the pharmacologic treatme

201 ot present in monkeys chronically exposed to antipsychotic medications, and not present in CR+ neuron

202 ment of schizophrenia remains dependent upon antipsychotic medications, which demonstrate D2 receptor

203 cerbation of symptoms despite treatment with antipsychotic medications.

204 1, are correlated with improved responses to antipsychotic medications.

205 hways associated with the effects of classic antipsychotic medications.

206 Patients were maintained on stable doses of antipsychotic medications.

207 or 10 mg in MoonLyte) added to their current antipsychotic medicine.

208 ride, amisulpride, and lamotrigine), used as antipsychotic medicines, were identified and confirmed b

209 nonantipsychotic medications vs placebos or antipsychotic monotherapy among adults with schizophreni

210 ia after having had two periods of different antipsychotic monotherapy.

211 and patients who had responded to first-line antipsychotics (n=12) were recruited.

212 in the study (22 with bipolar psychosis [18 antipsychotic naive or free], 16 with schizophrenia [14

213 ic naive or free], 16 with schizophrenia [14 antipsychotic naive or free], and 22 matched controls) a

214 f prediabetic states would be more common in antipsychotic naive patients with first-episode psychosi

215 nts with first-episode psychosis (14 of them antipsychotic naive) and 20 healthy volunteers underwent

216 nts with first-episode psychosis (14 of them antipsychotic naive) and 20 healthy volunteers underwent

217 compare TSPO availability in a predominantly antipsychotic-naive group of moderate-to-severely sympto

218 examining measures of glucose homeostasis in antipsychotic-naive individuals with first-episode schiz

219 moglobin A1c (HbA1c) levels in first-episode antipsychotic-naive individuals with first-episode schiz

220 Sixty-nine antipsychotic-naive inpatients and outpatients with schi

221 for the first time, in the dorsal caudate of antipsychotic-naive patients with FEP, which normalized

222 Twenty-eight antipsychotic-naive patients with first-episode psychosi

223 stigated the endogenous risk for diabetes in antipsychotic-naive schizophrenia and evaluated the risk

224 (95% confidence interval [CI], 1.71-5.41) in antipsychotic-naive schizophrenia compared with the gene

225 o, 3.64; 95% CI, 1.95-6.82) than the risk in antipsychotic-naive schizophrenia, after adjustment for

226 rotonin reuptake inhibitors, with or without antipsychotics, on the outcomes of interest.

227 y of antipsychotic drugs combined with other antipsychotic or nonantipsychotic medications vs placebo

228 ample sizes, and psychotic patients being on antipsychotics or not being in the first episode of thei

229 depressants (PR = 1.13; 95% CI = 1.07-1.19), antipsychotics (PR = 1.39; 95% CI = 1.21-1.60), and pote

230 amine D2/3 receptor occupancy data to inform antipsychotic prescribing for psychosis in Alzheimer's d

231 investigation, as it has implications beyond antipsychotic prescribing.

232 en (ACB) score of 3 or higher (PUM-ACB), any antipsychotic prescription (PUM-antipsychotic), and any

233 curring within 180 days before and after the antipsychotic prescription claim.

234 Many antipsychotics promote weight gain, which can lead to no

235 humans indicates that cannabidiol (CBD) has antipsychotic properties.

236 ng periods when individiduals were dispensed antipsychotics, psychostimulants, and drugs for addictiv

237 which displays behavioural deterioration on antipsychotic reduction that prevents discontinuation; p

238 he results suggest a harmful effect of other antipsychotics regarding self-harm compared with clozapi

239 The authors estimated the endogenous and antipsychotic-related risks for diabetes by using Cox pr

240 action of antipsychotics, and development of antipsychotic resistance.

241 The group receiving antipsychotic review but not the social intervention sho

242 Antipsychotic review plus the social interaction interve

243 Antipsychotic review significantly reduced antipsychotic

244 Eight homes were randomly assigned to antipsychotic review, to a social interaction interventi

245 rt a central pharmacokinetic contribution to antipsychotic sensitivity in Alzheimer's disease and imp

246 Pooled second-generation antipsychotics (SGAs) were associated with shorter TTR (

247 s with improved therapeutic profile.Atypical antipsychotics show reduced extrapyramidal side effects

248 ther they were experiencing any of 21 common antipsychotic side effects, vital signs were obtained, f

249 c interneurons and the mechanisms of typical antipsychotic side effects.

250 Addition of the antipsychotics, spiperone or haloperidol, resulted in re

251 Atypical antipsychotics such as olanzapine often induce excessive

252 to antipsychotic effects or represent novel antipsychotic targets.

253 ate of self-harm was higher for nonclozapine antipsychotics than for clozapine (hazard ratio: 1.36, 9

254 stimulants that exacerbate the disorder, and antipsychotics that ameliorate the disorder.

255 uld provide a path to develop more effective antipsychotic therapies.

256 irst-trimester exposure to second-generation antipsychotics, three major malformations were confirmed

257 The use of antipsychotics to manage challenging behaviour in adults

258 Composite [11]OMAR VT was HCs > antipsychotic treated SZCs > antipsychotic free SZCs.

259 ith failure to receive annual testing during antipsychotic treatment (adjusted odds ratio [OR], <1 fa

260 This was driven mainly by periods of no antipsychotic treatment (hazard ratio: 2.50, 95% CI: 1.5

261 nia and related disorders and </=6 months of antipsychotic treatment (N=404) were enrolled and follow

262 Neither aging nor changes in antipsychotic treatment accounted for the declines.

263 Head-to-head trials to guide antipsychotic treatment choices for paediatric psychosis

264 ent in other brain regions and persist after antipsychotic treatment has not been previously investig

265 We performed an updated meta-analysis of antipsychotic treatment in patients with delirium, based

266 ia and evaluated the risks added by starting antipsychotic treatment in people with schizophrenia.

267 al neurons prevented the negative effects of antipsychotic treatment on synaptic remodeling and cogni

268 ce of a role for rare functional variants in antipsychotic treatment response, pointing to a subset o

269 ations, including lithium, antiepileptic and antipsychotic treatment showed significant associations

270 Scale (PANSS) total score of at least 70 and antipsychotic treatment stability for the past 12 weeks

271 The risk for diabetes after starting antipsychotic treatment was significantly higher (adjust

272 onnectivity index that predicted response to antipsychotic treatment with high sensitivity and specif

273 Following 4 weeks of antipsychotic treatment, GABA levels in patients with FE

274 ocognitive functioning following 12 weeks of antipsychotic treatment.

275 malized in both regions following 4 weeks of antipsychotic treatment.

276 e classified as responders after 12 weeks of antipsychotic treatment.

277 the neural mechanisms underlying response to antipsychotic treatment.

278 asures at baseline and following 12 weeks of antipsychotic treatment.

279 in is a common and serious adverse effect of antipsychotic treatment.

280 bitor, as an adjunctive treatment to ongoing antipsychotic treatment.

281 nsequences of chronic illness, or effects of antipsychotic treatment.

282 t our findings are not due to the effects of antipsychotic treatment.

283 hizophrenia show poor response to first-line antipsychotic treatments and this is termed treatment-re

284 the comparative real-world effectiveness of antipsychotic treatments for patients with schizophrenia

285 re clinically meaningful differences between antipsychotic treatments with regard to preventing relap

286 e generalisability of these results to other antipsychotics, trial designs, and medical conditions re

287 atients enrolled in the multicenter Clinical Antipsychotic Trials of Intervention Effectiveness (CATI

288 Antipsychotic review significantly reduced antipsychotic use by 50% (odds ratio 0.17, 95% confidenc

289 While reductions in antipsychotic use can be achieved by using a "real world

290 rs (postmortem interval, age, and history of antipsychotic use) were considered.

291 tcomes included discontinuation of the index antipsychotic, use of an additional antipsychotic, incid

292 There is a perception that antipsychotics used in this context can be reduced or di

293 lozapine compared with initiating a standard antipsychotic was associated with greater effectiveness

294 hazard ratio (HR) associated with dispensed antipsychotics was 0.58 (95% CI, 0.39-0.88), based on 10

295 The National Pregnancy Registry for Atypical Antipsychotics was established to determine the risk of

296 ith dyslipidemia after being treated with an antipsychotic were assigned to take 1000 mg day(-1) metf

297 Several second-generation antipsychotics were superior to haloperidol in terms of

298 When pooled as a group, antipsychotics were superior to placebo/UC in terms of r

299 Information is limited about the effects of antipsychotics when used as mood stabilizer treatment.

300 ndidates for schizophrenia were enriched for antipsychotics, while those for bipolar disorder were en